PTC Therapeutics initiates open-label study for Atlauren - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

PTC Therapeutics initiates open-label study for Atlauren - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who received ataluren in a prior, PTC-sponsored clinical study. The primary objective of this study is to gain further information on the long-term safety and tolerability of ataluren, an investigational new drug. PTC launched a similar study in the United States in November 2010.